Data compiled by Redley Lamar · ChainSifter Intelligence
8Suppliers
10Customers
1Debt Items
20Related Chains
Source-Backed Evidence Depth
Organon & Co. (OGN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
20Total relationships
2Distinct source URLs
8High confidence
0.784Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Organon & Co. Suppliers
Ticker
Name
Confidence
Evidence
SEBELA-PHARMACEUTICALS
SEBELA-PHARMACEUTICALS
92%
On February 19, 2026, Organon entered into an exclusive license agreement with Sebela for the global rights to Miudella ®2, a hormone-free copper intrauterine device ("IUD") that was approved by the …
SHANGHAI-HENLIUS-BIOTECH-INC
SHANGHAI-HENLIUS-BIOTECH-INC
92%
In the first quarter of 2026, in anticipation of the expected launch of HLX-11 in the United States, the Company entered into an agreement with Henlius that amended the terms of the existing license …
Oss, Netherlands Women’s health Pandaan, Indonesia Cardiovascular, respiratory and dermatology Xochimilco, Mexico Cardiovascular and respiratory Most of our internal manufacturing sites have long-sta…
Reciprocal relationship from MRK graph: Reciprocal relationship from OGN graph: Oss, Netherlands Women’s health Pandaan, Indonesia Cardiovascular, respiratory and dermatology Xochimilco, Mexico Cardi…
SAMSUNG-BIOEPIS-CO-LTD
SAMSUNG-BIOEPIS-CO-LTD
90%
The Company has an agreement with Samsung Bioepis Co., Ltd. ("Samsung Bioepis") to develop and commercialize multiple pre-specified biosimilar candidates, which have since launched and are part of th…
Reciprocal relationship from JNJ graph: Reciprocal relationship from OGN graph: nd treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Jada uses…
nd treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Jada uses a low-level vacuum to encourage the physiologic contraction of the uterus to co…
Reciprocal relationship from ROIV graph: Reciprocal relationship from OGN graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from OGN graph: Reciprocal relationship from ROIV gra…
Organon & Co. Customers
Ticker
Name
Confidence
Evidence
LABORIE-MEDICAL-TECHNOLOGIES-CORPORATION
LABORIE-MEDICAL-TECHNOLOGIES-CORPORATION
90%
In January 2026, the Company divested the Jada System to Laborie for an aggregate payment of up to $ 465 million, comprised of consideration of $ 440 million, sub
nd treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Jada uses a low-level vacuum to encourage the physiologic contraction of the uterus to co…
Reciprocal relationship from JNJ graph: Reciprocal relationship from OGN graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from OGN graph: Reciprocal relationship from JNJ graph:…
es allow us to execute customer engagement strategies optimized across preferred channels and aimed at healthcare providers, patients and payors. Our global and local marketing employees focus on bui…
Reciprocal relationship from MRK graph: Reciprocal relationship from OGN graph: Reciprocal relationship from MRK graph: Reciprocal relationship from OGN graph: Reciprocal relationship from MRK graph:…
. All federal cases involving allegations of femur fractures have been transferred to a multidistrict litigation in the U.S. District Court for the District of New Jersey (“Femur Fracture MDL”). In t…
Reciprocal relationship from ORANY graph: Reciprocal relationship from OGN graph: . All federal cases involving allegations of femur fractures have been transferred to a multidistrict litigation in t…
Reciprocal relationship from ROIV graph: all, which could negatively affect our capacity for certain strategic transactions or our ability to make other important investments. In addition, high level…
LICENSING-ARRANGEMENTS-SHANGHAI-HENLIUS-BIOTECH-
LICENSING-ARRANGEMENTS-SHANGHAI-HENLIUS-BIOTECH-
62%
a normal and recurring nature. All intercompany transactions and accounts within Organon have been eliminated. These interim statements should be read in conjunction with the audited financial statem…
SUN-PHARMACEUTICAL-INDUSTRIES-LIMITED
SUN-PHARMACEUTICAL-INDUSTRIES-LIMITED
62%
quests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Sho…
Organon & Co. Debt Obligations
Instrument
Description
Confidence
Evidence
OGN-DEBT
Debt stack $8.6B
90%
Market cache reports total debt of $8.6B.
Organon & Co. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Organon & Co..
Organon & Co. Ownership
Holder
Name
Confidence
Evidence
OGN-OWNER-BLACKROCK-INC
BlackRock, Inc.
90%
13F overlay lists BlackRock, Inc. as top holder; 623 tracked holders.
